On 10 November 2025, the FDA announced significant pharmaceutical labeling updates for menopausal hormone therapies, requiring the removal of outdated boxed warnings and the incorporation of refined, evidence-based safety information. The update introduces age-specific and timing-specific benefit–risk details for systemic estrogen and estrogen–progestogen products, along with streamlined safety statements for local vaginal estrogen therapies. These FDA safety-related labeling changes directly impact regulatory labeling compliance, prompting updates to CCDS, CCSI, SmPCs, and regional labels to ensure alignment with current scientific data. The revision emphasizes the need for precise drug labeling compliance, consistent terminology, and harmonized global labeling to support clear, accurate communication for prescribers and patients.
Select Mandate HA
Select Mandate Function